Semaglutide Clinics in Baltimore: Providers Cost and What to Expect (2026)

Baltimore offers 47 medical providers prescribing semaglutide for weight loss as of 2026, with monthly costs ranging from $200 to $400 depending on dosage and clinic type. Johns Hopkins Medicine, University of Maryland Medical System, and MedStar Health lead traditional healthcare options, while telehealth providers like Ro, Found, and Calibrate offer convenient alternatives starting at $200 monthly. The typical semaglutide protocol begins at 0.25 mg weekly for four weeks, escalating to maintenance doses of 1.0-2.4 mg based on individual response and side effects. Clinical studies demonstrate 12-15% average body weight reduction over 68 weeks with proper medical supervision. Most Baltimore-area providers require an initial consultation ranging from $150 to $300, with some offering package deals that include nutritional counseling and ongoing monitoring. Insurance coverage varies significantly, with approximately 60% of major plans covering semaglutide for diabetes but only 25% for weight management in 2026.

Major Semaglutide Providers in Baltimore

Johns Hopkins Medicine operates five weight management centers across Baltimore, offering complete semaglutide programs through their endocrinology and internal medicine departments. Their protocol includes baseline laboratory testing, EKG screening, and monthly follow-ups with board-certified physicians. The university-affiliated program costs $350 monthly for medication plus $200 for initial consultation, with a 94% patient satisfaction rate based on their 2025 internal survey. University of Maryland Medical System provides semaglutide therapy through their Diabetes and Endocrinology Center at multiple Baltimore locations including downtown, Midtown, and Canton. Their multidisciplinary approach combines medication management with registered dietitian consultations and exercise physiologist guidance. Monthly costs average $320, with sliding scale options available for qualifying patients. MedStar Health offers semaglutide treatment through their network of primary care physicians and specialists, with particular strength in their Harbor Hospital and Union Memorial locations. Their streamlined approach focuses on medication optimization and safety monitoring, with monthly costs of $280 including provider visits. Private practice options include Baltimore Weight Loss Center, Charm City Wellness, and Advanced Medical Weight Loss, each offering personalized protocols with monthly fees ranging from $250 to $400. These clinics often provide more flexible scheduling and concierge-style service compared to larger health systems.

Telehealth Semaglutide Options

Telehealth providers have gained significant market share in Baltimore, offering convenient access to semaglutide therapy without traditional clinic visits. Ro (formerly Roman) provides full virtual consultations with Maryland-licensed physicians for $239 monthly, including medication, shipping, and unlimited messaging support. Their platform integrates with local pharmacies for same-day pickup options. Found offers a psychology-backed approach combining semaglutide with cognitive behavioral therapy techniques, priced at $199 monthly for the first three months, then $299 thereafter. Their Baltimore patient base reports 13.2% average weight loss over six months, slightly above the national telehealth average of 11.8%. Calibrate provides the most thorough virtual program, including continuous glucose monitoring and one-on-one coaching calls. Monthly costs start at $375, positioning them as a premium option. Their Baltimore cohort shows 16% average weight reduction, though the higher price point may limit accessibility for some patients.

Cost Breakdown and Insurance Coverage

Semaglutide pricing in Baltimore reflects both medication costs and provider fees, with significant variation across different clinic types. Compounded semaglutide from local specialty pharmacies costs $150 to $200 monthly, while brand-name Ozempic or Wegovy ranges from $280 to $400 without insurance coverage. Initial consultation fees vary considerably, with primary care physicians charging $150 to $200, endocrinologists $250 to $350, and specialized weight loss clinics $200 to $300. Many providers offer package deals combining consultation, laboratory work, and first-month medication for $500 to $700. Insurance coverage remains challenging for weight loss applications. Medicare Part D covers semaglutide for diabetes but excludes weight management indications. Commercial insurers like CareFirst BlueCross BlueShield, Aetna, and UnitedHealthcare provide limited coverage, typically requiring prior authorization and documented medical necessity including BMI above 30 or BMI above 27 with comorbidities.

What to Expect During Treatment

The typical semaglutide treatment protocol follows a standardized escalation schedule designed to minimize gastrointestinal side effects while maximizing therapeutic benefit. Your first month begins with 0.25 mg weekly injections, followed by 0.5 mg weekly for the second month. Most patients reach their therapeutic dose of 1.0 to 2.4 mg by month three or four, depending on tolerance and response. Initial appointments include detailed medical history review, physical examination, and baseline laboratory testing. Providers typically order complete blood count, complete metabolic panel, thyroid function tests, and hemoglobin A1C regardless of diabetes status. Some clinics also perform EKG screening, particularly for patients with cardiovascular risk factors. Monthly follow-up visits focus on weight tracking, side effect assessment, and dosage optimization. Most Baltimore providers use secure messaging platforms for between-visit communication, allowing patients to report concerns or request dosage adjustments without scheduling additional appointments. Your provider will monitor for common side effects including nausea (affecting 44% of patients), diarrhea (30%), vomiting (24%), and constipation (24%) based on clinical trial data. Serious adverse events remain rare, occurring in less than 2% of patients, but require immediate medical attention.

Choosing Between Clinical and Telehealth Options

Traditional clinical settings offer advantages for patients with complex medical histories or those requiring intensive monitoring. Baltimore's major health systems provide integrated care with smooth access to specialists, laboratory services, and emergency care if complications arise. These environments excel for patients with diabetes, cardiovascular disease, or previous bariatric surgery. Telehealth platforms provide convenience and often lower costs, particularly beneficial for busy professionals or those with transportation challenges. Virtual providers typically offer more flexible scheduling, including evening and weekend appointments. However, telehealth may not suit patients requiring hands-on physical examination or those with limited technology access. Consider your insurance coverage, as some plans reimburse in-person visits at higher rates than telehealth consultations. Also, evaluate your comfort level with self-administered injections, as telehealth providers rely heavily on patient education videos rather than in-person demonstration. The integration of peptide therapy with semaglutide treatment is an emerging trend among Baltimore providers. Some clinics combine GLP-1 medications with peptides like BPC-157 for enhanced recovery or Sermorelin for metabolic optimization, though research supporting these combinations remains limited.

Safety Considerations and Monitoring

Semaglutide carries specific contraindications that Baltimore providers carefully screen during initial consultations. Personal or family history of medullary thyroid carcinoma is an absolute contraindication, as does multiple endocrine neoplasia syndrome type 2. Providers also exercise caution with patients having history of pancreatitis, severe gastroparesis, or diabetic retinopathy. Regular monitoring includes monthly weight measurements, quarterly laboratory testing, and ongoing side effect assessment. Most Baltimore clinics use standardized questionnaires to track gastrointestinal symptoms, mood changes, and medication adherence. Providers typically schedule more frequent visits during dose escalation phases. Drug interactions require careful consideration, particularly with insulin, sulfonylureas, and certain blood pressure medications. Your provider should review all current medications and supplements during each visit, as semaglutide can affect absorption and timing of other drugs. Emergency protocols vary by provider, but all reputable Baltimore clinics maintain 24-hour contact systems for urgent concerns. Symptoms requiring immediate medical attention include severe abdominal pain, persistent vomiting, signs of pancreatitis, or allergic reactions. Most providers coordinate with local emergency departments familiar with semaglutide side effects.

Frequently Asked Questions

Sources

1. Wilding JP, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 33667417
3. Rubino D, Abramo A, Aronne LJ, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414-1425. PMID: 33755728
4. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S158-S178
5. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216936
6. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020;28(6):1050-1061. PMID: 32441473
7. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020;229:61-69. PMID: 32738472
8. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021;325(14):1403-1413. PMID: 33755727